Olema Pharmaceuticals, Inc. — Form SCHEDULE 13D/A
Filed October 16, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 18/100
What the filing says
Biotechnology Value Fund L.P. filed an amended Schedule 13D/A on October 16, 2026, regarding beneficial ownership of Olema Pharmaceuticals, Inc. The filing header and metadata are present, but the specific details of the ownership stake—share count, percentage held, prior vs. current position, and reason for amendment—are not disclosed in the provided document excerpt.
Why this rating
Amendment alone is routine; without disclosed % ownership or triggering changes, cannot assess materiality to 243M-cap biotech.
See more from October 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.